Purpose 18F-labeled amino acids (AAs) as tumor-specific imaging agents play a critical role in hepatocellular carcinoma (HCC) imaging. In this work, we evaluated the synthesis and biological properties of a simple 18F-labeled glutamate analogue, [18F]AlF-1,4,7-triazacyclononane-1,4,7-triacetic-acid-2-S-(4-isothiocyanatobenzyl))-l-glutamate ([18F]AlF-NOTA-NSC-GLU) for HCC imaging via one-step reaction sequence. Methods [18F]AlF-NOTA-NSC-GLU was synthesized via the one-step reaction sequence from NOTA-NSC-GLU. In order to investigate the imaging value of [18F]AlF-NOTA-NSC-GLU in HCC, we conducted PET/CT imaging and competitive binding of [18F]AlF-NOTA-NSC-GLU in human Hep3B tumor-bearing mice. The transport mechanism of [18F]AlF-NOTA-NSC-GLU was determined by competitive inhibition and protein incorporation experiments in vitro. Results [18F]AlF-NOTA-NSC-GLU was prepared without decay-corrected radiochemical yield of 29.3 ± 5.6% (n=10) within 20 min. In vitro competitive inhibition experiments demonstrated that Na+-dependent Systems XAG-, B0+, ASC and minor XC- were involved in the uptake of [18F]AlF-NOTA-NSC-GLU, with Na+-dependent System XAG- possibly playing a more dominant role. Protein incorporation studies of the Hep3B human hepatoma cell line found almost no protein incorporation. Micro-PET/CT imaging with [18F]AlF-NOTA-NSC-GLU showed good tumor-to-background contrast in Hep3B human hepatoma-bearing mouse models. After [18F]AlF-NOTA-NSC-GLU injection, the tumor-to-liver uptake ratio of [18F]AlF-NOTA-NSC-GLU was 2.06 ± 0.17 at 30 min post-injection. In vivo competitive binding experiments exhibited that the tumor-to-liver uptake ratio decreased by the addition of the inhibitors to block the system XAG-. Conclusion We have successfully synthesized [18F]AlF-NOTA-NSC-GLU as a novel PET tracer with good radiochemical yield and high radiochemical purity. Our findings indicate that [18F]AlF-NOTA-NSC-GLU might have good clinical potential as a PET tumor-detecting agent for HCC imaging.
Purpose 18F-labeled amino acids (AAs) as tumor-specific imaging agents play a critical role in hepatocellular carcinoma (HCC) imaging. In this work, we evaluated the synthesis and biological properties of a simple 18F-labeled glutamate analogue, [18F]AIF-1,4,7-triazacyclononane-1,4,7-triacetic-acid-2-S-(4-isothiocyanatobenzyl))-l-glutamate ([18F]AIF-NOTA-NSC-GLU) for HCC imaging via one-step reaction sequence. Methods [18F]AIF-NOTA-NSC-GLU was synthesized via the one-step reaction sequence from NOTA-NSC-GLU. In order to investigate the imaging value of [18F]AIF-NOTA-NSC-GLU in HCC, we conducted PET/CT imaging and competitive binding of [18F]AIF-NOTA-NSC-GLU in human Hep3B 2.1-7 tumor-bearing mice. The transport mechanism of [18F]AIF-NOTA-NSC-GLU was determined by competitive inhibition and protein incorporation experiments in vitro. Results [18F]AIF-NOTA-NSC-GLU was prepared with decay-corrected radiochemical yield of 29.3 ± 5.6% (n=10) within 20 min. In vitro competitive inhibition experiments demonstrated that Na+-dependent Systems XAG-, B0+, ASC and minor XC- were involved in the uptake of [18F]AIF-NOTA-NSC-GLU, with Na+-dependent System XAG- possibly playing a more dominant role. Protein incorporation studies of the Hep3B 2.1-7 human hepatoma cell line found almost no protein incorporation. Micro-PET/CT imaging with [18F]AIF-NOTA-NSC-GLU showed good tumor-to-background contrast in Hep3B 2.1-7 human hepatoma-bearing mouse models. After [18F]AIF-NOTA-NSC-GLU injection, the tumor-to-liver uptake ratio of [18F]AIF-NOTA-NSC-GLU reached the peak at 30 min post-injection (2.06 ± 0.17). In vivo competitive binding experiments exhibited that the tumor-to-liver uptake ratio decreased by the addition of the inhibitors to block the system XAG-. Conclusion We have successfully synthesized [18F]AIF-NOTA-NSC-GLU as a novel PET tracer with good radiochemical yield and high radiochemical purity. Our findings indicate that [18F]AIF-NOTA-NSC-GLU might have good clinical potential as a PET tumor-detecting agent for HCC imaging.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.